Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019
December 18 2018 - 8:30AM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that
Scott Garland, Portola’s president and chief executive officer,
will provide a corporate update on Tuesday, January 8, at 7 a.m. PT
(10 a.m. ET). The live webcast will be available on the
Company's website at www.portola.com.
Webcast DetailsTo access the
live investor webcast on Tuesday, January 8, at 7 a.m. PT (10 a.m.
ET), go to the Investor Relations section of the company’s website
at http://investors.portola.com. A replay will be available for 30
days.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], the first and only antidote for patients treated
with rivaroxaban and apixaban when reversal of anticoagulation is
needed due to life-threatening or uncontrolled bleeding, and
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness. The company also is
advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
|
|
|
|
|
Investor
Contact: |
Media
Contact: |
|
|
|
Cara Miller |
Patrick Ryan |
|
|
|
Portola
Pharmaceuticals |
Pure
Communications |
|
|
|
ir@portola.com |
pryan@purecommunications.com |
|
|
|
|
|
|
|
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024